Heterocyclic compounds and methods of use

US8232273B2 · kind B2 · utility

Assignees

• Genentech, Inc. · US
• Abbott Laboratories · US
• THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH · AU

Inventors

• Jonathan Bayldon Baell · Ivanhoe, AU
• Chinh Thien Bui · Melbourne, AU
• Peter Colman · Melbourne, AU
• Peter Edward Czabotar · Melbourne, AU
• Danette Dudley · Ann Arbor, US
• Wayne Fairbrother · South San Francisco, US
• John A. Flygare · Burlingame, US
• Guillaume Laurent Lessene · Melbourne, AU
• Chudi Ndubaku · Oakland, US
• George Nikolakopoulos · Melbourne, AU
• Brad Sleebs · Morgan, AU
• Brian John Smith · Melbourne, AU
• Keith G. Watson · Melbourne, AU
• Steven W. Elmore · Northbrook, US
• Lisa A. Hasvold · Grayslake, US
• Andrew M. Petros · Mundelein, US
• Andrew J. Souers · Libertyville, US
• Zhi-Fu Tao · Vernon Hills, US
• Le Wang · Xi'an, CN
• Xilu Wang · Grayslake, US
• Kurt Deshayes · San Francisco, US

Key dates

• Filing date: Dec 17, 2009
• Grant date: Jul 31, 2012
• Expiry date: Nov 18, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/06
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

In one aspect, the present invention provides for a compound of Formula Iin which the variable X1a, X1b, X1c, X1d, Q, A, R1, B, L, E, and the subscripts m and n have the meanings as described herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.